AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2020
Dec 4, 2020
32159_dirs_2020-12-03_7950da57-ace0-4fd5-a976-7326ef40541e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03
Reporting Person: Hunder Naomi (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $1.08 | 2029-03-07 | Common Stock (44259) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (30677) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (22840) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (23681) | Direct | |
| Stock option (right to buy) | $6.65 | 2030-09-30 | Common Stock (75410) | Direct |
Footnotes
F1: 25% of the shares vested on January 14, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2: 25% of the shares shall vest on March 4, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter.
F3: 25% of the shares shall vest on July 1, 2021 and the remaining shares shall vest in 36 equal monthly instalments thereafter.
F4: The shares shall vest in 48 equal monthly installments beginning on October 18, 2020.
F5: The shares shall vest in 48 equal monthly installments beginning on October 22, 2020.